• Press Release/Announcement
  • Published February 2006

Nimodipine Capsules (marketed as Nimotop).

This U.S. Food and Drug Administration alert reminds health care professionals that nimodipine should only be administered orally, and that intravenous or parenteral administration can cause serious adverse events.

Back to Top